Author

D. Lazarevic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Evolutionary Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Bardelli· 1 shared A. Crisanti· 1 shared A. Spitaleri· 1 shared C. Del Vecchio· 1 shared C. Volponi· 1 shared d. Cirillo· 1 shared E. Franchin· 1 shared E. Lavezzo· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Bardelli

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DCs targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

L. Lopez, L. G. Morosi, F. La Terza, P. Bourdely, G. Rospo, R. Amadio, G. M. Piperno, V. Russo, C. Volponi, S. Vodret, S. Joshi, F. Giannese, D. Lazarevic, G. Germano, P. Stoitzner, , F. Benvenuti

The paper shows that DC-based therapy enhances CD8 T cell responses to neoantigens in lung tumors, particularly in high TMB tumors.

bioRxiv · Jan 26, 2024 · PreprintImmunology

Rapid longitudinal SARS-CoV-2 intra-host emergence of novel haplotypes regardless of immune deficiencies

L. Manuto, M. Grazioli, A. Spitaleri, P. Fontana, L. Bianco, L. Bertolotti, M. Bado, G. Mazzotti, F. Bianca, F. Onelia, G. Lorenzin, F. Simeoni, D. Lazarevic, E. Franchin, C. Del Vecchio, , S. Toppo

The paper analyzes SARS-CoV-2 genomic data from a quarantined Italian town, showing rapid intra-host emergence of novel viral haplotypes within two weeks, regardless of immune status or symptoms.

bioRxiv · Dec 22, 2021 · PreprintEvolutionary Biology